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receptor-α DNA methylation and breast
composition in adolescent Chilean girls
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José L Santos5, John Shepherd6 and Karin B Michels1*
Abstract
Background: Estrogen receptor-α (ER-α) is a transcriptional regulator, which mediates estrogen-dependent breast
development, as well as breast tumorigenesis. The influence of epigenetic regulation of ER-α on adolescent breast
composition has not been previously studied and could serve as a marker of pubertal health and susceptibility to
breast cancer. We investigated the association between ER-α DNA methylation in leukocytes and breast composition in
adolescent Chilean girls enrolled in the Growth and Obesity Cohort Study (GOCS) in Santiago, Chile. Breast
composition (total breast volume (BV; cm3), fibroglandular volume (FGV; cm3), and percent fibroglandular volume
(%FGV)) was measured at breast Tanner stage 4 (B4). ER-α promoter DNA methylation was assessed by
pyrosequencing in blood samples collected at breast Tanner stages 2 (B2; n = 256) and B4 (n = 338).
Results: After adjusting for fat percentage at breast density measurement, ER-α methylation at B2, and cellular
heterogeneity, we observed an inverse association between B4 average ER-α DNA methylation and BV and FGV.
Geometric mean BV was 15% lower (95% CI: − 28%, − 1%) among girls in the highest quartile of B4 ER-α methylation
(6.96–23.60%) relative to the lowest (0.78–3.37%). Similarly, FGV was 19% lower (95% CI: − 33%, − 2%) among girls in
the highest quartile of B4 ER-α methylation relative to the lowest. The association between ER-α methylation and
breast composition was not significantly modified by body fat percentage and was not influenced by pubertal timing.
Conclusions: These findings suggest that the methylation profile of ER-α may modulate adolescent response to
estrogen and breast composition, which may influence breast cancer risk in adulthood.
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Background
Estrogen receptor-α (ER-α) is a ligand-activated transcrip-
tional regulator, which mediates the action of estrogen
and contributes to normal breast development and breast
tumorigenesis [1]. Collectively, estrogen and its receptors
(ER-α and β) regulate breast epithelial cell proliferation,
differentiation, and apoptosis [1]. A majority of literature
concerning ER-α is focused on its role in breast cancer;
notably, two thirds of all breast cancer cases are associated
with overexpression of ER-α [2, 3]. These ER+ tumors
respond well to selective estrogen receptor modulators
(e.g., tamoxifen), which competitively bind to estrogen re-
ceptors to prevent estrogen-dependent cancer growth [4].
DNA methylation of the ER-α promoter blocks the ex-
pression of ER-α [5–8]. Consequently, the DNA methyla-
tion profile of ER-α is currently being explored as a
predictor of breast cancer incidence and prognosis
(i.e., lower ER-α DNA methylation may be indicative of in-
creased breast cancer risk). Due to its vital role in mediat-
ing the mammary tissue response to estrogen, ER-α
methylation could also be considered as a potential
marker of pubertal health, particularly in relation to mam-
mary gland development.
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ER-α plays a crucial role in mediating the action of es-
trogen in normal breast tissue and in regulating mam-
mary gland development [9, 10]. ER-α knockout mice
display decreased mammary epithelial cell proliferation
and limited ductal growth [11, 12]. ER-α is also a major
contributor to normal reproductive development [13,
14]. Knockout ER-α mice and mice with mutated ER- α
are infertile and display a decreased response to estrogen
[13, 14], suggesting normal ER-α expression is necessary
to regulate the response to estrogen and guide normal
pubertal development.
There have been no studies to date exploring the
epigenetic regulation of ER-α in relation to adolescent
breast development in humans. Variants in the ER-α
gene (ESR1) have been associated with the increased
percent fibroglandular volume (%FGV) in pre- and post-
menopausal women [15–17], supporting a role of ER-α
in regulating breast tissue composition in humans. The
objective of this study was to analyze ER-α promoter
DNA methylation in leukocytes during the pubertal time
period (at breast Tanner stages 2 (B2) and 4 (B4)), in re-
lation to total breast volume (BV), fibroglandular (FGV),
and %FGV measured at B4 in a prospective cohort of
girls enrolled in the Growth and Obesity Cohort Study
(GOCS) in Santiago, Chile. Given the potential influ-
ence of the peripheral conversion of estrogen on ER-α
regulation, the majority of which occurs in adipose tis-
sue, we also evaluate potential effect modification of
this relation by adolescent adiposity (body fat percen-
tage) [18]. Further, we analyze effect modification by
exposure to endocrine-disrupting chemicals (EDCs;
phthalates and phenols), which mimic or antagonize
the effects of endogenous hormones [19–21]. The
methylation profile of ER-α in adolescence may repre-
sent an additional marker of pubertal health and a po-
tential marker of breast cancer risk in adulthood.
Results
Demographics of Chilean girls enrolled in the Growth and
Obesity Cohort Study
This study includes 429 Chilean girls enrolled in the
Growth and Obesity Cohort Study (GOCS) and
assessed for breast development at B4 (n = 345) and
ER-α promoter DNA methylation at B2 (n = 256) and
B4 (n = 338). The median age at methylation assess-
ment was 10.1 years at B2 and 11.1 years at B4. It
should be noted that the B2 assessment may not accur-
ately represent age at thelarche, of which the median
age was 9.3 years. The median age at menarche was
11.9 years. Body fat percentage was measured at B4,
concurrent with breast composition measurements
(median fat percentage = 26 %). The remaining demo-
graphics for this cohort are summarized in Table 1.
ER-α methylation is moderately correlated between
B2 and B4
ER-α methylation at B2 and B4 was assessed across 10
CpG sites (located within the 5′ untranslated region
Table 1 Demographic characteristics of 429 Chilean girls participating
in GOCS and included in this analysis
Covariate Breast Tanner
stage
Demographics
Age at visit, years B2 n 256
Median 10.1
25th–75th
percentiles
9.4–10.8
B4 n 358
Median 11.1
25th–75th
percentiles
10.6–11.8
Fibroglandular
volume
(% DV/BV)
FGV n 345
Median 76.8
25th–75th
percentiles
58.7–98.4
BV n 345
Median 200.5
25th–75th
percentiles
144.7–278.7
%FGV n 345
Median 37.9
25th–75th
percentiles
27.2–53.4
Age at menarche,
years
n 379
Median 11.9
25th–75th
percentiles
11.2–12.4
Fat percentage
at Tanner 4
n 357
Median 26.0
25th–75th
percentiles
22.5–29.8
Maternal
education
Completed
secondary
n 328
% 76.5
Completed
post-secondary
n 101
% 23.5
ER-α methylation B2 n 256
Median 6.0
25th–75th
percentiles
4.0–8.8
B4 n 338
Median 7.0
25th–75th
percentiles
4.3–9.4
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(5′UTR) of the ESR1 gene) in blood samples from ado-
lescent Chilean girls. Due to the high correlation in
percent methylation across the interrogated CpG loci
(Spearman rho = 0.65–98; Additional file 1: Figure S1),
we summarized the methylation level of the ER-α pro-
moter by the mean across all sites. Average ER-α
methylation was moderately correlated between B2 and
B4 (Spearman rho = 0.244, p = 0.002); the intra-
individual correlation in methylation across Tanner
stage was not improved after correction for cellular
heterogeneity (Spearman rho = 0.215; p = 0.009). We
also compared the level of methylation between B2 and
B4 (paired t test) and found no statistically significant
differences between these time points.
ER-α methylation at B4 is inversely associated with B4
breast composition
We first investigated the influence of ER-α methylation
at B2 and B4 on adolescent (B4) breast composition, in-
cluding total breast volume (BV; cm3), fibroglandular
volume (FGV; cm3), and percent fibroglandular volume
(%FGV). Average B2 ER-α methylation was not associ-
ated with any of these measures of breast composition
in either unadjusted or adjusted models (Tables 2, 3,
and 4). In contrast, we detected an inverse association
between average B4 ER-α methylation and total BV, as
well as FGV, after adjusting for B2 ER-α methylation,
fat percentage at density measurement, and cellular
heterogeneity (Fig. 1; Tables 2 and 3). Among girls in
the same quartile of B2 ER-α methylation, those in the
highest quartile (Q4) of B4 methylation (6.96–23.60%)
had 15% lower (0.85; 95% confidence interval (CI):
0.72–0.99) geometric mean BV than girls in the lowest
quartile (Q1) of B4 methylation (0.78–3.37%), adjusting
for fat percentage and cellular heterogeneity. Similarly,
geometric mean FGV was 19% lower (0.81; 95% CI:
0.67–0.98) among girls in the highest B4 methylation
quartile relative to the lowest, adjusting for B2 ER-α
methylation, fat percentage, and cellular heterogeneity.
These associations were consistent after further adjust-
ment for age at breast density measurement and mater-
nal education (Tables 2 and 3). We observed a similar
relation between B4 ER-α methylation and BV in
models that were not adjusted for B2 ER-α methylation.
However, these associations did not reach statistical sig-
nificance (p > 0.05). Given the similar influence of B4
ER-α methylation on total BV and FGV, there was no
association between ER-α methylation and %FGV. The
impact of ER-α methylation on FGV and total BV at B4
did not related to age at menarche. Neither B2 nor B4
methylation was significantly associated with the timing
of menarche, before or after adjustment for potential
confounding variables (Table 5).
Table 2 ER-α methylation at B4 is inversely associated with B4
total BV in Chilean girls enrolled in GOCS
Stage label Relative change in geometric mean BV (95% CI)
Model 1a Model 2b Model 3c
Tanner 2
Quartilesd
Q2 0.91 (0.79–1.05) 0.89 (0.76–1.03) 0.89 (0.77–1.04)
Q3 1.04 (0.90–1.21) 1.05 (0.90–1.22) 1.05 (0.90–1.22)
Q4 1.03 (0.89–1.19) 1.02 (0.88–1.19) 1.03 (0.89–1.20)
Linear modele
1.03 (0.96–1.09) 1.01 (0.95–1.08) 1.02 (0.95–1.09)
Tanner 4
Quartilesd
Q2 0.91 (0.82–1.00) 0.95 (0.86–1.06) 0.95 (0.86–1.06)
Q3 1.03 (0.93–1.14) 0.99 (0.89–1.10) 0.99 (0.89–1.10)
Q4 0.94 (0.85–1.04) 0.92 (0.83–1.02) 0.92 (0.83–1.02)
Linear modele
0.98 (0.94–1.03) 0.96 (0.91–1.00) 0.96 (0.91–1.00)
Tanner 2 (2 and 4)f
Quartilesd
Q2 0.89 (0.77–1.03) 0.90 (0.77–1.05) 0.90 (0.77–1.05)
Q3 1.07 (0.92–1.24) 1.08 (0.92–1.27) 1.08 (0.92–1.27)
Q4 1.00 (0.86–1.17) 1.02 (0.87–1.19) 1.01 (0.86–1.19)
Linear modele
1.02 (0.95–1.09) 1.00 (0.94–1.08) 1.00 (0.93–1.08)
Tanner 4 (2 and 4)g
Quartilesd
Q2 0.93 (0.81–1.07) 0.95 (0.82–1.10) 0.95 (0.82–1.10)
Q3 1.10 (0.94–1.28) 1.03 (0.88–1.21) 1.03 (0.88–1.21)
Q4 0.89 (0.77–1.04) 0.85 (0.72–0.99)* 0.85 (0.72–0.99)*
Linear modele
0.98 (0.91–1.04) 0.93 (0.86–1.00)* 0.93 (0.86–1.00)*
aAssociation with mean ER-α methylation adjusting for fat percentage at
breast density measurement
bAssociation with cell composition corrected mean ER-α methylation adjusting
for fat percentage at breast density measurement
cModel 2 additionally adjusted for age at breast density measurement and
maternal education
dQuartiles for Tanner 2 methylation: Q1 [1.17, 4.05], Q2 (4.05, 6.04], Q3 (6.04,
8.85], Q4 (8.85, 29.30]; quartiles for Tanner 2 methylation after correction for
cellular heterogeneity: Q1 [0.98, 3.49], Q2 (3.49, 5.03], Q3 (5.03, 7.34], Q4 (7.34,
24.8]. Quartiles for Tanner 4 methylation: Q1 [1.10, 4.27], Q2 (4.27, 7.05], Q3
(7.05, 9.37], Q4 (9.37, 32.00]; quartiles for Tanner 4 methylation after correction
for cellular heterogeneity: Q1 [0.78, 3.37], Q2 (3.37, 5.28], Q3 (5.28, 6.96], Q4
(6.96, 23.60]
eReporting relative change in geometric mean BV per doubling of
percent methylation
fModeling B2 and B4 ER-α methylation simultaneously, reporting association
with B2 ER-α methylation
gModeling B2 and B4 ER-α methylation simultaneously, reporting association
with B4 ER-α methylation
*p<0.05, Wald test
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Table 3 ER-α methylation at B4 is inversely associated with B4
FGV in Chilean girls enrolled in GOCS
Stage label Relative change in geometric mean FGV (95% CI)
Model 1a Model 2b Model 3c
Tanner 2
Quartilesd
Q2 0.95 (0.80–1.12) 0.92 (0.77–1.10) 0.93 (0.77–1.11)
Q3 1.10 (0.92–1.31) 1.13 (0.94–1.37) 1.14 (0.95–1.37)
Q4 1.04 (0.88–1.25) 1.04 (0.87–1.24) 1.05 (0.88–1.27)
Linear modele
1.02 (0.95–1.10) 1.01 (0.93–1.09) 1.01 (0.94–1.09)
Tanner 4
Quartilesd
Q2 0.91 (0.80–1.03) 0.94 (0.83–1.07) 0.94 (0.83–1.08)
Q3 0.99 (0.87–1.12) 0.98 (0.86–1.11) 0.99 (0.87–1.13)
Q4 0.94 (0.83–1.07) 0.92 (0.81–1.04) 0.92 (0.81–1.05)
Linear modele
0.97 (0.92–1.03) 0.95 (0.90–1.01) 0.96 (0.90–1.01)
Tanner 2 (2 and 4)f
Quartilesd
Q2 0.93 (0.78–1.11) 0.92 (0.76–1.10) 0.92 (0.76–1.11)
Q3 1.14 (0.95–1.37) 1.20 (0.99–1.44) 1.20 (0.99–1.45)
Q4 1.02 (0.85–1.23) 1.05 (0.87–1.27) 1.05 (0.87–1.27)
Linear modele
1.02 (0.94–1.10) 1.01 (0.93–1.10) 1.02 (0.93–1.11)
Tanner 4 (2 and 4)g
Quartilesd
Q2 0.90 (0.76–1.06) 0.90 (0.76–1.07) 0.90 (0.76–1.07)
Q3 1.07 (0.89–1.28) 1.05 (0.87–1.26) 1.05 (0.87–1.27)
Q4 0.91 (0.76–1.09) 0.81 (0.67–0.98)* 0.81 (0.67–0.98)*
Linear modele
0.97 (0.90–1.05) 0.91 (0.83–0.99)* 0.91 (0.83–0.99)*
aAssociation with mean ER-α methylation adjusting for fat percentage at
breast density measurement
bAssociation with cell composition corrected mean ER-α methylation adjusting
for fat percentage at breast density measurement
cModel 2 additionally adjusted for age at breast density measurement and
maternal education
dQuartiles for Tanner 2 methylation: Q1 [1.17, 4.05], Q2 (4.05, 6.04], Q3
(6.04, 8.85], Q4 (8.85, 29.30]; quartiles for Tanner 2 methylation after
correction for cellular heterogeneity: Q1 [0.98, 3.49], Q2 (3.49, 5.03], Q3
(5.03, 7.34], Q4 (7.34, 24.8]. Quartiles for Tanner 4 methylation: Q1 [1.10,
4.27], Q2 (4.27, 7.05], Q3 (7.05, 9.37], Q4 (9.37, 32.00]; quartiles for Tanner
4 methylation after correction for cellular heterogeneity: Q1 [0.78, 3.37],
Q2 (3.37, 5.28], Q3 (5.28, 6.96], Q4 (6.96, 23.60]
eReporting relative change in geometric mean FGV per doubling of
percent methylation
fModeling B2 and B4 ER-α methylation simultaneously, reporting association
with B2 ER-α methylation
gModeling B2 and B4 ER-α methylation simultaneously, reporting association
with B4 ER-α methylation
*p<0.05, Wald test
Table 4 ER-α methylation is not associated with B4 %FGV in
Chilean girls enrolled in GOCS
Stage label Relative change in geometric mean %FGV (95% CI)
Model 1a Model 2b Model 3c
Tanner 2
Quartilesd
Q2 1.04 (0.94–1.14) 1.03 (0.93–1.15) 1.04 (0.94–1.15)
Q3 1.05 (0.95–1.17) 1.08 (0.97–1.20) 1.08 (0.97–1.21)
Q4 1.01 (0.92–1.12) 1.01 (0.91–1.13) 1.02 (0.92–1.13)
Linear modele
1.00 (0.96–1.04) 1.00 (0.95–1.04) 1.00 (0.95–1.04)
Tanner 4
Quartilesd
Q2 1.01 (0.93–1.09) 0.99 (0.91–1.07) 0.99 (0.92–1.07)
Q3 0.96 (0.89–1.04) 0.99 (0.91–1.07) 1.00 (0.92–1.08)
Q4 1.01 (0.93–1.09) 1.00 (0.93–1.08) 1.01 (0.93–1.09)
Linear modele
0.99 (0.96–1.02) 1.00 (0.96–1.03) 1.00 (0.97–1.04)
Tanner 2 (2 and 4)f
Quartilesd
Q2 1.04 (0.93–1.15) 1.02 (0.91–1.14) 1.02 (0.91–1.14)
Q3 1.07 (0.95–1.19) 1.10 (0.99–1.23) 1.10 (0.98–1.23)
Q4 1.01 (0.91–1.13) 1.03 (0.92–1.15) 1.04 (0.93–1.16)
Linear modele
1.00 (0.95–1.05) 1.01 (0.96–1.06) 1.01 (0.96–1.06)
Tanner 4 (2 and 4)g
Quartilesd
Q2 0.97 (0.88–1.07) 0.95 (0.86–1.05) 0.96 (0.86–1.06)
Q3 0.98 (0.88–1.09) 1.02 (0.91–1.14) 1.02 (0.92–1.14)
Q4 1.02 (0.92–1.14) 0.96 (0.86–1.08) 0.96 (0.86–1.08)
Linear modele
1.00 (0.96–1.05) 0.99 (0.94–1.04) 0.99 (0.94–1.04)
aAssociation with mean ER-α methylation adjusting for fat percentage at
breast density measurement
bAssociation with cell composition corrected mean ER-α methylation adjusting
for fat percentage at breast density measurement
cModel 2 additionally adjusted for age at breast density measurement and
maternal education
dQuartiles for Tanner 2 methylation: Q1 [1.17, 4.05], Q2 (4.05, 6.04], Q3
(6.04, 8.85], Q4 (8.85, 29.30]; quartiles for Tanner 2 methylation after
correction for cellular heterogeneity: Q1 [0.98, 3.49], Q2 (3.49, 5.03], Q3
(5.03, 7.34], Q4 (7.34, 24.8]. Quartiles for Tanner 4 methylation: Q1 [1.10,
4.27], Q2 (4.27, 7.05], Q3 (7.05, 9.37], Q4 (9.37, 32.00]; quartiles for Tanner
4 methylation after correction for cellular heterogeneity: Q1 [0.78, 3.37],
Q2 (3.37, 5.28], Q3 (5.28, 6.96], Q4 (6.96, 23.60]
eReporting relative change in geometric mean %FGV per doubling of
percent methylation
fModeling B2 and B4 ER-α methylation simultaneously, reporting association
with B2 ER-α methylation
gModeling B2 and B4 ER-α methylation simultaneously, reporting association
with B4 ER-α methylation
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Associations between ER-αmethylation and breast composition
are not modified by body fat percentage
We next evaluated whether the association between
ER-α methylation and breast composition was modified
by body fat percentage at B4. Percent body fat did not
significantly modify the association between either B2 or
B4 ER-α methylation and breast composition (results
not shown). Likewise, percent body fat did not signifi-
cantly interact with log-transformed ER-α methylation
(%) to influence menarcheal age.
Exposure to EDCs may modify the association between
B2 ER-α methylation and B4 breast composition
Similarly, we postulated exposure to exogenous chemicals
that mimic or antagonize the body’s endogenous
hormones may modify the relation between ER-α methy-
lation and breast composition. Urinary biomarkers of 26
phenols and phthalates were measured among 200 girls at
B1 and B4; of these girls, DNA methylation results were
Fig. 1 Breast composition by quartiles of average ER-α methylation.
Quartiles for Tanner 2 methylation after correction for cellular heterogeneity:
Q1 [0.98, 3.49], Q2 [3.49, 5.03], Q3 [5.03, 7.34], Q4 [7.34, 24.8].
Quartiles for Tanner 4 methylation after correction for cellular
heterogeneity: Q1 [0.78, 3.37], Q2 [3.37, 5.28], Q3 [5.28, 6.96], Q4
[6.96, 23.60]
Table 5 ER-α methylation is not associated with age at menarche
in Chilean girls enrolled in GOCS
Stage label Relative time to menarche (95% CI)
Model 1a Model 2b Model 3c
Tanner 2
Quartilesd
Q2 0.98 (0.96–1.00) 0.99 (0.97–1.02) 1.00 (0.97–1.03)
Q3 0.99 (0.97–1.01) 0.98 (0.95–1.00) 0.98 (0.95–1.00)
Q4 0.98 (0.96–1.00) 0.98 (0.96–1.01) 0.99 (0.96–1.02)
Linear modele
0.99 (0.98–1.00) 0.99 (0.98–1.00) 0.99 (0.98–1.01)
Tanner 4
Quartilesd
Q2 1.00 (0.98–1.02) 1.01 (0.98–1.03) 1.01 (0.98–1.03)
Q3 0.99 (0.97–1.02) 0.99 (0.97–1.01) 0.99 (0.97–1.01)
Q4 1.00 (0.97–1.02) 1.01 (0.98–1.03) 1.01 (0.98–1.03)
Linear modele
1.00 (0.99–1.01) 1.00 (0.99–1.01) 1.00 (0.99–1.01)
Tanner 2 (2 and 4)f
Quartilesd
Q2 0.98 (0.95–1.01) 0.99 (0.96–1.03) 1.00 (0.97–1.03)
Q3 0.99 (0.96–1.02) 0.98 (0.94–1.01) 0.97 (0.94–1.01)
Q4 0.98 (0.95–1.01) 0.98 (0.95–1.01) 0.98 (0.95–1.01)
Linear modele
0.99 (0.98–1.01) 0.99 (0.98–1.00) 0.99 (0.98–1.00)
Tanner 4 (2 and 4)g
Quartilesd
Q2 1.00 (0.97–1.03) 1.01 (0.98–1.04) 1.01 (0.98–1.04)
Q3 1.01 (0.98–1.04) 1.00 (0.97–1.03) 1.00 (0.97–1.03)
Q4 0.99 (0.96–1.03) 1.01 (0.98–1.05) 1.01 (0.98–1.05)
Linear modele
1.00 (0.99–1.02) 1.01 (0.99–1.02) 1.01 (0.99–1.02)
aRelative time to menarche associated with mean ER-α methylation estimated
via accelerated failure time model
bAssociation with cell composition corrected mean ER-α methylation
cModel 2 additionally adjusted for fat percentage at breast density
measurement and maternal education
dQuartiles for Tanner 2 methylation: Q1 [1.17, 4.05], Q2 (4.05, 6.04], Q3 (6.04, 8.85],
Q4 (8.85, 29.30]; Quartiles for Tanner 2 methylation after correction for cellular
heterogeneity: Q1 [0.98, 3.49], Q2 (3.49, 5.03], Q3 (5.03, 7.34], Q4 (7.34, 24.8].
Quartiles for Tanner 4 methylation: Q1 [1.10, 4.27], Q2 (4.27, 7.05], Q3 (7.05, 9.37],
Q4 (9.37, 32.00]; Quartiles for Tanner 4 methylation after correction for cellular
heterogeneity: Q1 [0.78, 3.37], Q2 (3.37, 5.28], Q3 (5.28, 6.96], Q4 (6.96, 23.60]
eReporting relative time to menarche per doubling of percent methylation
fModeling B2 and B4 ER-α methylation simultaneously, reporting association
with B2 ER-α methylation
gModeling B2 and B4 ER-α methylation simultaneously, reporting association
with B4 ER-α methylation
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available for 149 girls at B2 and 186 at B4. We previously
observed no statistically significant difference in the influ-
ence of B1 and B4 phenol and phthalate concentrations
on adolescent breast density in this population [publica-
tion accepted - in process]. Biomarker concentrations of
monocarboxyisononyl phthalate (MCNP) significantly
modified the influence of log-transformed B2 ER-α methy-
lation on BV (likelihood ratio test (LRT), p = 0.036) and
FGV (LRT, p = 0.014). The association between B2 ER-α
methylation and FGV was also modified by average levels
of both benzophenone-3 (LRT, p = 0.023) and methyl
paraben urinary concentration (LRT, p = 0.041). In each of
these cases, the impact of B2 ER-α methylation on either
BV or FGV appeared to be in opposite directions for girls
with low biomarker concentrations compared to those
with high biomarker concentrations (Fig. 2; Table 6).
However, none of these associations, stratified by dichoto-
mized EDC category, reached statistical significance
(Table 6; p > 0.05). The influence of B4 ER-α methylation
on the breast measurements was not significantly modi-
fied by any of the measured EDCs. While we did detect a
significant interaction between propyl paraben and
log-transformed B2 ER-α methylation on the timing of
menarche, the interaction was no longer statistically sig-
nificant after the exclusion of one influential observation.
We note that these associations should be interpreted
with caution given the limited power to account for the
role of type-I error inflation.
Fig. 2 Associations between mean ER-α methylation and breast composition significantly (LRT, p<0.05) modified by adolescent EDC exposure.
Plotting the association between log-transformed cell composition corrected Tanner 2 ER-α methylation and a) log-transformed BV, stratified by
dichotomized MCNP levels; b) log-transformed FGV, stratified by dichotomized MCNP levels; c) log-transformed FGV, stratified by dichotomized
benzophenone levels; d) log-transformed FGV, stratified by dichotomized methyl paraben levels. Average EDC concentrations were dichotomized
by the median. Orange = high; green = low
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Discussion
In this prospective cohort of Chilean girls, average B4
ER-α promoter DNA methylation was inversely associated
with total BV and FGV measured at B4, adjusting for B2
ER-α methylation, cellular heterogeneity, and fat percent-
age at breast density measurement. Among individuals
that were in the same quartile of B2 ER-α methylation,
those in the lowest quartile of B4 ER-α methylation had
greater BV and FGV than those in the highest quartile at
B4. In other words, we observed a relative change in breast
composition between groups that had the greatest diver-
gence in ER-α methylation after B2. Due to similar asso-
ciations with both total BV and FGV, epigenetic regulation
of ER-α was not associated with %FGV in adolescence.
Although ER-α has been reported to regulate reproductive
development [13, 14], we did not observe it to be associ-
ated with menarcheal age. This could be attributed to the
fact that endometrium growth is modulated by both ER-α
and β [22, 23]. These findings were also not modified by
adolescent body fat percentage, which suggests peripheral
conversion of estrogen did not modulate the association
between epigenetic regulation of its receptor and breast
development at this stage. Lastly, we provide cursory evi-
dence to support effect modification by exposure to spe-
cific EDCs on the relation between B2 ER-α methylation
and B4 breast composition.
Promoter methylation of ER-α is highly correlated with
its expression pattern [7, 8, 24, 25]. Accordingly, the
observed inverse association between ER-α methylation
and FGV and BV may reflect diminished sensitivity to
estrogen-stimulated mammary epithelial cell proliferation
and ductal growth [11, 12]. The association with ER-α
methylation varied by developmental stage (B2 versus B4);
only B4 ER-α methylation was associated with adolescent
breast composition. Given B4 ER-α methylation and
breast composition were measured concurrently, it is pos-
sible that decreased B4 ER-α methylation was a conse-
quence of breast composition. However, mouse knockouts
of ERS1 suggest ER-α is a requisite for normal mammary
gland and reproductive development [10, 26, 27]. Direct
action of estrogen on its receptors initiates mammary epi-
thelial cell proliferation by inducing expression of prolifer-
ative markers (e.g., Ki67). Subsequently, ER-α expression
is reduced, while the proliferative markers remain
expressed [10, 28], allowing for continued ductal growth.
The inverse association at B4 is potentially due to contin-
ued downregulation of the ESR1 gene. ESR1 downregula-
tion also correlates with the upregulation of inhibitory
markers (e.g., TGF-β), which induce cell cycle arrest and
may reduce epithelial proliferation in mammary tissue in
the later stages of breast maturation [28–30]. Shepherd et
al. report that the peak total FGV occurs at B4; hence, in
this cohort, breast composition measurements were per-
formed only at B4 [31]. Consequently, we cannot report
on the association between B2 ER-α methylation and initi-
ation of breast budding, beginning at B2. Perhaps we did
not see an inverse association between B2 epigenetic regu-
lation of ER-α and B4 breast composition due to the ne-
cessity for estrogen-stimulated mammary epithelial cell
proliferation at the onset of ductal development. As breast
maturation advances toward B4, however, there is a pro-
gressive reduction in ER-α expression associated with di-
minished mammary cell proliferation and enhanced
ductal differentiation [28, 32]. Further, the B2 methylation
assessment does not truly represent thelarche in this co-
hort and it is possible this may affect our analysis at B2.
We can only provide cursory evidence of the role of ado-
lescent exposure to EDCs on breast development. However,
exposure to high levels of EDCs appears to have differential
effects on the relation between B2 ER-α methylation and
BV and FGV. Among girls with high EDC exposure, we ob-
served an inverse association between B2 methylation and
FGV, suggesting that EDC exposure may decrease expres-
sion of ER-α and subsequently, FGV. The positive associ-
ation between B2 ER-α methylation and BV among girls
exposed to high levels of EDCs may be attributed to in-
creased peripheral conversion of estrogen and subsequent
increases in adiposity and BV.
Modulation of adolescent breast development by ER-α
regulation could have future implications for breast can-
cer risk. Increased proportion of dense breast tissue
(breast density, percent fibroglandular volume) in adults
Table 6 Relative change in geometric mean B4 breast composition
(95% CI) associated with a doubling of cell composition
corrected mean Tanner 2 ER-αmethylation that is significantly (LRT,
p<0.05) modified by specific EDC biomarker concentrations
Outcome EDC categoryb
EDC LRT p valuea High Low
Total breast volume (cm3)
MCNP 0.036 1.03
(0.93–1.14)
0.97
(0.87–1.09)
Fibroglandular volume (cm3)
MCNP 0.014 1.06
(0.95–1.19)
0.93
(0.82–1.07)
Benzophenone-3 0.023 0.93
(0.82–1.05)
1.07
(0.94–1.21)
Methyl paraben 0.041 0.95
(0.83–1.09)
1.04
(0.93–1.17)
aLikelihood ratio test (LRT) p-value comparing a model for log transformed
breast composition that includes log-transformed cell composition corrected
mean ER-α methylation, log-transformed EDC biomarker concentration, fat
percentage and age at breast density measurement, and maternal education,
to a model that additionally includes an interaction between log-transformed
methylation level and log transformed EDC biomarker concentration.
Restricting to models for which the statistical interaction term significantly
(p<0.05) improved model fit
bRelative change in geometric mean breast composition associated with a
doubling of percent methylation, stratifying by dichotomized (by the median)
EDC metabolite concentrations, adjusting for fat percentage and age at breast
density measurement, and maternal education
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is one of the strongest and most consistent risk factors
for breast cancer [33–35]. Peak breast density is postu-
lated to be established during adolescence [36, 37], at
which time the susceptibility of the developing mam-
mary tissue to carcinogens is strongly enhanced. Corres-
pondingly, Boyd and colleagues have speculated that
women at high risk of breast cancer could be identified
at an early age based on a breast density measurement
[37]. The importance of pubertal development in breast
cancer etiology is further highlighted by the inverse
association between both age at breast bud development
(thelarche) and age at menarche and breast cancer
incidence [38–40]. In this study, epigenetic regulation of
ER-α was not associated with age at menarche. This is
perhaps due to our analysis of ER-α in blood, as pubertal
timing is largely regulated by neuronal ER-α [41, 42]. The
hypothalamic-pituitary-gonadal axis is also coordinated by
many hormones (gonadotropic releasing hormone, testos-
terone, etc.) and endogenous and exogenous factors be-
yond estrogen [43], which may explain the lack of
association between epigenetic regulation of ER-α and pu-
bertal timing. Finally, it is possible this epigenetic signa-
ture is transient, instigating changes in pubertal breast
development during a key developmental window of sus-
ceptibility for breast cancer. However, it is vital that ER-α
methylation be assessed at additional time points through-
out the life course to determine whether this methylation
signature remains stable through post-pubertal mammary
gland development.
In addition to addressing a major gap in our under-
standing of how ER-α regulation modifies adolescent
breast development in humans, our study has a number
of strengths. This investigation was conducted in a large,
well-characterized longitudinal pediatric cohort. Assess-
ment of ER-α methylation at two pubertal time points fa-
cilitated the identification of time-varying associations
between epigenetic regulation of ER-α and breast com-
position. Measurement of body fat and urinary EDC
biomarkers enabled examination of endogenous and
exogenous modifiers of hormone regulation and potential
impact on breast development. However, despite our rela-
tively large sample size, after adjusting for multiple testing,
we had limited power to identify significant interactions
between EDC biomarker concentrations and ER-α methy-
lation on breast composition. Another limitation of this
study was the assessment of ER-α methylation in blood ra-
ther than breast tissue; however, in a pediatric cohort, bi-
opsies of the target tissue (breast) are not feasible.
Gene-specific methylation profiles are mildly correlated
among whole blood and breast tumor samples; however,
blood-derived DNA typically displays a lower methylation
frequency for particular genes when compared to breast
or tumor tissues [44, 45]. This limits the potential for
ER-α blood DNA promoter methylation to serve as a
surrogate marker of adolescent breast tissue methylation.
However, as blood DNA methylation is currently being
explored as a marker of breast cancer risk and breast
tumor development [46], the blood epigenetic profile of
ER-α may serve as a marker of adolescent breast compos-
ition. Additionally, due to our restriction to a Chilean co-
hort, we also note that the observed associations may not
be generalizable to all populations as race/ethnicity may
be associated with differential methylation profiles [47]
and/or varied timing of breast maturation [48]. Finally, we
do not yet know which of these girls may develop breast
cancer in their lifetime, and thus, we cannot conclude that
adolescent breast composition or the regulation of ER-α is
predictive of breast cancer development in adulthood.
Conclusion
Our study outlines the potential influence of ER-α epi-
genetic regulation on breast development in humans.
Specifically, we identified an inverse association between
increased ER-α DNA promoter methylation and total
BV and FGV at B4 in Chilean girls. Future work in this
research area should consider other endogenous and ex-
ogenous factors (e.g., dietary patterns) influencing ado-
lescent ER-α methylation and implications for breast
composition. To better characterize the role of ER-α in
initiating breast development, researchers should also
consider the analysis of the ER-α methylation profile and
expression pattern at B1, prior to the onset of mammary
gland development. Further, as breast cancer typically
develops later in life, researchers should consider asses-
sing ER-α methylation at later stages of development
and during periods of significant hormonal shifts (B5,
during pregnancy, and prior to menopause). Finally, it is
important to note that follow-up proof-of-concept stud-
ies in humans and animal models are needed to verify
our findings. For example, in vitro and/or in vivo experi-
mental analyses should be applied to elucidate the feed-
back relation between estrogen levels and epigenetic
regulation of ER-α during this critical window of breast
development in adolescence. In addition, it will be im-
portant for future studies to assess the role of other bio-
logical pathways and genetic components, which may be
modified by environmental factors and associated with
pubertal development. In conclusion, this study greatly
expands upon the current literature surrounding the role
of ER-α in breast development by providing evidence in
humans to support ER-α as a key modifier of pubertal
breast composition and a potential risk marker for
breast cancer in adulthood.
Methods
Study population
This study includes a subcohort of 429 Chilean girls en-
rolled in the Growth and Obesity Cohort Study (GOCS)
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with blood samples collected at B2 and/or at B4. Details
of GOCS have been previously described [49]. Briefly,
1190 singleton children born at term (37–42 weeks) were
enrolled in the study in 2006 when they were 2.6–4.0 years
of age. All participants had a birth weight between 2500
and 4500 g. Children with any physical, medical, or endo-
crine diseases that might impact growth or puberty were
excluded from the study. Children were physically
assessed annually from 2006 to 2010 at the Institute of
Nutrition and Food Technology Health Clinic in Santiago,
Chile. From 2011 onward, the participants were physically
assessed every 6 months. GOCS children were recruited
from public nursery schools and are thus representative of
low- to middle-income Chilean children from the south-
east area of Santiago. The study protocol was approved by
the Ethics Committee of the Institute of Nutrition and
Food Technology, University of Chile. All parents and/or
legal guardians gave signed informed consent prior to the
data collection and children gave their assent.
Dense breast tissue assessment
Assessment of breast density at B4 in GOCS has been pre-
viously described [36]. Briefly, breast development was
assessed visually and by palpation by a single female
trained dietitian (kappa with pediatric endocrinologist =
0.9) at clinical visits approximately every 6 months, begin-
ning in 2009, using Tanner’s rating scale [50, 51]. At the
first B4 visit, breast fibroglandular volume (FGV; cm3),
total breast volume (BV; cm3), and percentage of fibro-
glandular volume (%FGV = FGV/BV × 100) were mea-
sured via dual-energy X-ray absorptiometry (DXA) in the
left and right breasts. DXA has been previously validated
and correlates strongly with mammography [31, 52, 53].
The dosage of radiation exhibited by this assessment is ex-
tremely low, lower than that received during a transcon-
tinental flight, limiting any significant health risks
associated with this X-ray method [54]. Each breast was
scanned using GE iDXA system software (version 13.6,
GE Healthcare, Madison, WI, USA). Breast compos-
ition was derived from a two-compartment model of
adipose and fibroglandular tissues using the software
developed by Dr. Shepherd and colleagues, Depart-
ment of Radiology and Biomedical Imaging, University
of California, San Francisco (version 5). A quality control
phantom that contained reference breast density materials
was scanned throughout the study to ensure stable cali-
bration. Values from the left and right breasts are averaged
for all analyses.
Biospecimen collection
Fasting blood samples were collected at B2 and B4 for
ER-α methylation analysis. DNA was extracted from the
blood leukocytes using the QIAamp DNA Blood Mini Kit
(Qiagen). Fasting spot urine samples were collected
between 10 AM and 12 PM in polypropylene sterile cups
and were immediately vortexed and aliquoted. They were
collected at breast Tanner stages 1 (B1) and B4 for analysis
of exposure to EDCs.
ER-α methylation analysis
Polymerase chain reaction (PCR)
Genomic DNA was treated with bisulphite salt using the
EZ DNA Methylation-Gold kit (Zymo Research, Cat.
No. D5007) according to the manufacturer’s protocol.
DNA was amplified in 20-μl PCR reactions, containing
10 μl of Hot StarTaq Master Mix Kit (Qiagen, Cat. No
203446), 150 ng of each primer, and ~ 20 ng modified
DNA. PCR was performed with one cycle of 95 °C for
15 min, 40 cycles of 95 °C for 30 s, 57–63 °C for 30 s,
and 72 °C for 30 s, followed by one cycle of 72 °C for
10 min. The reverse primer included a 5′-biotin label to
allow subsequent analysis by pyrosequencing. Primer se-
quences can be found in (Additional file 1: Table S1).
PCRs were performed in duplicate using 96-well plates.
Each PCR plate contained the participants’ DNA sam-
ples, as well as three dH2O samples as non-template
controls and three samples with known methylation sta-
tus as positive controls.
Pyrosequencing
Pyrosequencing was performed on a PyroMark Q24 MD
pyrosequencer (Qiagen, Cat. No 9001514) according to the
manufacturer’s recommendations. The primers were de-
signed using the primer design program “PSQ assay”
(Biotage), using the ER-α gene sequence that was obtained
from the GenBank entry on NCBI (Additional file 1:
Table S1).
Assay validation was carried out on samples of known
methylation status, using the EpiTect Control DNA and
Control DNA Set (Qiagen, Cat. No. 59568). All pyrose-
quencing analyses were performed in duplicate. If the
duplicates of the individual samples showed a differ-
ence < 5% of methylation, the average methylation of the
two measurements was used for further analyses. When
the difference was > 5%, a third measurement was per-
formed. Due to the high correlation in percent methyla-
tion across the 10 interrogated CpG loci, ER-α
methylation was summarized by average methylation
across pyrosequenced loci 1–8. Loci 9 and 10 were not in-
cluded in this average due to low resolution at the end of
the sequencing reads in approximately 50% of the sam-
ples. Average ER-α methylation independent of blood
composition was estimated by regressing log-transformed
ER-α methylation on the proportion of monocytes,
basophils, eosinophils, neutrophils, and lymphocytes,
stratified by breast Tanner stage at ER-α methylation
measurement. The exponentiated residuals were used in
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subsequent models that we note were corrected for cellu-
lar heterogeneity.
Endocrine-disrupting chemicals
Urinary biomarker concentrations of 26 phenols and
phthalates were measured among a subset of 200 GOCS
girls at breast B1 and B4. EDC assays were performed at
the Centers for Disease Control and Prevention (CDC)
National Center for Environmental Health Laboratory
using previously described analytical methods [55, 56].
The analysis of blinded specimens by the CDC laboratory
was determined not to constitute engagement in human
subjects’ research. Concentrations below the limit of de-
tection (LOD) were given an imputed value equal to
LOD/sqrt(2). EDC biomarker concentrations (ng/ml) were
corrected for specific gravity. Dilution adjustment was
performed using the formula Pc = P[(1.015 − 1)/(SG − 1)],
where Pc is the specific gravity-corrected biomarker con-
centration, P is the observed biomarker concentration, SG
is the specific gravity of the urine sample, and 1.015 is the
median SG of the study population [55–58]. The analysis
was restricted to the subset of 21 EDCs for which bio-
marker concentrations were above the LOD in at least
75% of the samples. For this study, EDC measurements
were averaged across B1 and B4.
Age at menarche
Prior to the onset of B4, girls were asked to report their
first menstrual bleeding at each 6-month visit. After
achieving B4, girls were contacted by study dietitians every
3 months to survey whether the girl had reached menar-
che. During this phone interview, a questionnaire was
used to differentiate menarche from other potential causes
of vaginal bleeding, such as vaginal infection, urinary in-
fection, or trauma. Longitudinal follow-up of participants
enabled the confirmation of menarche onset.
Covariates
Additional covariates included in this analysis were age at
methylation assessment (B2 and B4), body fat percentage,
and maternal education. All additional covariates were mea-
sured at B4. Maternal education status was self-reported by
mothers at an in-clinic study visit and categorized as sec-
ondary or post-secondary for this study. Compared with
BMI, body fat percentage is a more precise measurement of
adolescent fat distribution. Fat percentage was estimated at
each visit using Tanita-BC-418 MA bioelectrical impedance
measurements (Tanita-Corporation, Tokyo, Japan), accord-
ing to the manufacturer’s guidelines and at a measurement
frequency of 50 kHz (accuracy 0.1 kg) [59].
Statistical analyses
All breast measurements were log-transformed prior to
analysis. Linear models were used to estimate the
association between ER-α methylation and breast compos-
ition, adjusting for fat percentage at breast density meas-
urement. We considered models additionally adjusted for
cellular heterogeneity and further adjusted for age at
breast density measurement and maternal education. We
independently modeled the association between B2 aver-
age ER-α methylation and breast composition (N = 177;
N = 164 correcting for cellular heterogeneity), as well as
the association between average B4 ER-α methylation and
breast composition (N = 329; N = 303 correcting for cellu-
lar heterogeneity). To identify time-dependent associa-
tions between ER-α methylation and breast composition,
we also simultaneously modeled the influence of both B2
ER-α methylation and B4 ER-α methylation on these
breast measurements (N = 161; N = 142 correcting for cel-
lular heterogeneity). ER-α methylation was modeled both
as quartiles and continuously as log-transformed percent
methylation. Estimated associations and 95% confidence
intervals (CI) between ER-α methylation and breast mea-
surements were exponentiated to provide the percent
change in geometric mean breast density measurement.
When modeling methylation continuously, we report the
percent change in geometric mean breast density meas-
urement given a doubling in percent methylation. Acceler-
ated failure time models were used to assess the influence
of ER-α methylation on time to menarche, assuming a
Weibull distribution. For incident cases, survival time was
the age at menarche, estimated based on the time between
the self-reported date of first menses and date of birth.
Survival time for right-censored individuals was the age at
last clinic visit, based on the time between the date of last
visit and date of birth. Similar to the breast measurement
models, time to menarche was modeled as a function of
B2 ER-α methylation and B4 ER-α methylation both sep-
arately and together, adjusting for cellular heterogeneity.
To assess whether B4 fat percentage significantly modified
the association between log-transformed B2 ER-α methy-
lation and breast measurement, we compared the fit of a
model with and without an interaction term between
these two dependent variables (likelihood ratio test
(LRT)), adjusting for cellular heterogeneity. We similarly
evaluated whether there was a statistically significant
interaction between log-transformed average EDC bio-
marker concentration and log-transformed B2 ER-α
methylation on breast measurement, adjusting for cellular
heterogeneity and fat percentage. Each biomarker was
modeled separately. Analogously, we analyzed effect
modification by both fat percentage and EDC exposure on
the association between B4 ER-α methylation and breast
measurement, as well as on the impact of B2 ER-α methy-
lation and B4 ER-α methylation on time to menarche, re-
spectively. Among models significantly modified by EDC
biomarker concentration (LRT, p < 0.05), the association
between log-transformed ER-α methylation and breast
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measurement is reported stratified by dichotomized EDC
level (high vs low relative to the median). All analyses
were performed using R version 3.4.1 and visualized
using ggplot2.
Additional file
Additional file 1: Figure S1. Correlation across CpG sites at B2 and B4
(Spearman rho = 0.65–98). Table S1: Primer sequences and positions.
(DOCX 592 kb)
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